Crossmark

Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteers

Crossref DOI link: https://doi.org/10.1038/s41380-026-03465-y

Published Online: 2026-02-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fournier, Céline

Buchy, Danièle

Mohr, Susanne https://orcid.org/0009-0009-4594-8229
Pähler, Axel

Jacobsen, Bjoern https://orcid.org/0000-0003-0782-6190
Norcross, Roger

Pflieger, Philippe

Sewing, Sabine

Greiter-Wilke, Andrea https://orcid.org/0000-0002-6460-5135
Kuennecke, Basil https://orcid.org/0000-0001-5883-935X
Schmitt, Christophe https://orcid.org/0000-0001-8001-5584
Morrison, Mary

Marchesi, Maddalena

Holiga, Stefan

Gerlach, Irene

Hoener, Marius C. https://orcid.org/0000-0001-6510-6250
License Information

Text and Data Mining valid from 2026-02-04

Version of Record valid from 2026-02-04
More Information

Article History

Received: 23 July 2025

Revised: 19 December 2025

Accepted: 25 January 2026

First Online: 4 February 2026

Competing interests

: CF, DB, SM, AP, BJ, RN, PP, SS, AGW, BK, CS, MM, MM, SH, IG and MCH are employees of F. Hoffmann-La Roche, Ltd. and may own stock or stock options.

Document is current

Any future updates will be listed below